SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on June 14, 2002; DOI 10.1182/blood-2002-01-0230. This Article Full Text (PDF) All Versions of this Article: 2002-01-0230v1 100/7/2349    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Maynadie, M. Articles by Feuillard, J. Search for Related Content PubMed PubMed Citation Articles by Maynadie, M. Articles by Feuillard, J. Social Bookmarking                   What's this? Submitted January 25, 2002 Accepted April 22, 2002 Immunophenotypic clustering of myelodysplastic syndromes Marc Maynadie, Francoise Picard, Bernard Husson, Bernard Chatelain, Yvan Cornet, Genevieve Le Roux, Lydia Campos, Alex Dromelet, Pascalle Lepelley, Helene Jouault, Michele Imbert, Michelle Rosenzwadj, Veronique Verge, Philippe Bissieres, Martine Raphael, Marie Christine Bene, and Jean Feuillard* Service d'Hematologie Biologique, CHU Bocage, Dijon, France Service d'Hematologie Biologique AP-HP, Hopital Cochin, Paris, France Laboratoire de Biologie Clinique, Hopital de Jolimont, Haine Saint Paul, Belgium Laboratoire d'Hematologie, Cliniques Universitaires UCL Mont Godinne, Yvoir, Belgium Service d'Hematologie Biologique, AP-HP, Hopital Avicenne et EA 3406 ATHSCO, Universite Paris 13, Bobigny, France Laboratoire d'Hematologie, Hopital Nord, CHU Saint Etienne, Saint Etienne, France Laboratoire d'Hematologie A, Hopital Calmette, CHU Lille, France Laboratoire d'Hematologie AP-HP, Hopital Henri Mondor, Creteil, France Laboratoire d'Immuno-Hematologie AP-HP, Hopital Saint-Antoine, Paris, France Laboratoire d'Immunologie, Faculte de Medecine, Vandoeuvre-Les-Nancy, France * Corresponding author; email: jean.feuillard{at}avc.ap-hop-paris.fr. Myelodysplastic syndromes (MDS) are heterogeneous diseases of bone marrow cell precursors for which immunophenotypic characterization is still considered irrelevant in spite of the accuracy and sensitivity of flow cytometry techniques. The aim of this study was to determine whether immunophenotypic abnormalities could be defined in MDS and could correlate with the FAB classification and cytogenetics. Analysis was performed on 275 bone marrow samples (207 MDS patients, 68 controls) and 25 control blood samples. Immunophenotyping was based on a primary gating of blast cells, monocytes and granulocytes according to CD45 antigen expression and side scatter light diffraction. Immunophenotypic hierarchical clustering was performed to analyze the results. The data obtained show that (i) immunophenotypic clustering partly discriminates patients with RAEB/RAEB-T, CMML and RA/RARS for CD45lo blast cells and patients with RA/CMML, RARS and RAEB/RAEB-T for CD45hi/SShi granulocytes, (ii) the most discriminating markers were CD16, CD34, CD36, CD38, CD71 and HLA-DR for blast cells and CD11b, CD13, CD33, CD36 CD38, CD71 and HLA-DR for CD45hi/SShi granulocytes, (iii) clusters related to CD34 expression were associated with high levels of blast cells on bone marrow smears (iv) clusters related to high levels of CD36 expression on CD45lo blast cells and/or CD45hi/SShi granulocytes were associated with a poor IPSS'score and (v) high levels of CD71 expression on CD45hi/SShi granulocytes were associated with the RARS category. These results demonstrate a close relationship between immunophenotypic abnormalities and bone marrow dysplasia and suggest that flow cytometry could be a useful tool in the future for the characterization of myelodysplastic syndromes. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: P. L. Greenberg, Z. Sun, K. B. Miller, J. M. Bennett, M. S. Tallman, G. Dewald, E. Paietta, R. van der Jagt, J. Houston, M. L. Thomas, et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996) Blood, September 17, 2009; 114(12): 2393 - 2400. [Abstract] [Full Text] [PDF] M. Cazzola Flow cytometry immunophenotyping for diagnosis of myelodysplastic syndrome Haematologica, August 1, 2009; 94(8): 1041 - 1043. [Full Text] [PDF] F. E. Craig and K. A. Foon Flow cytometric immunophenotyping for hematologic neoplasms Blood, April 15, 2008; 111(8): 3941 - 3967. [Abstract] [Full Text] [PDF] A. A. van de Loosdrecht, T. M. Westers, A. H. Westra, A. M. Drager, V. H. J. van der Velden, and G. J. Ossenkoppele Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry Blood, February 1, 2008; 111(3): 1067 - 1077. [Abstract] [Full Text] [PDF] D. A. Wells, M. Benesch, M. R. Loken, C. Vallejo, D. Myerson, W. M. Leisenring, and H. J. Deeg Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation Blood, July 1, 2003; 102(1): 394 - 403. [Abstract] [Full Text] [PDF]

	Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020